Introduction
============

The incidence and risk of invasive fungal infections (IFIs) continue to rise. The epidemiology of IFI has changed over time and is thought to be affected by patient factors, environmental considerations, and antifungal exposure. What was once a disease primarily caused by *Candida albicans*, IFIs caused by both *C. albicans* and invasive molds, predominantly *Aspergillus* species, have been increasing.[@b1-idr-10-035],[@b2-idr-10-035] These changes have driven the need for better methods of organism and species identification.

IFIs are insidious. Infections have often become well established by the time positive diagnostic evidence is found. The complexity of these infections necessitates rapid diagnosis and treatment. In recent years, the identification of rapid diagnostic methods and new antifungal agents has advanced the armamentarium for IFI management. Despite these improvements, consensus regarding how best to utilize these diagnostic methods and the optimal time to start antifungal treatment is still evolving.

In the Middle East, there is limited information available about the real-world burden of IFI, including epidemiology, mortality, treatment patterns, and resource utilization associated with these infections. The objectives of this study were therefore to document the microbiologic profile of IFI in Lebanon and Saudi Arabia and to describe the antifungal treatment received by these patients, in terms of drug selection and appropriateness, and to document hospital resource utilization and clinical outcomes among patients with these infections.

Methods
=======

Study design
------------

It was the responsibility of the study investigators (SIs) to have approval of the study from the local IRB/ethics committee. All sites submitted this study at their local institutions and received approval or exemption; no centralized ethics approval was sought for this study. In all cases, informed consent was not required for this non-interventional medical chart review study. This study is a retrospective, observational medical chart review that took place at five study sites in Saudi Arabia (two sites) and Lebanon (three sites). The purpose of this study is to describe the epidemiology, mortality, treatment patterns, and resource utilization associated with IFI for each country. Note that this analysis is descriptive of each country, not comparative between countries or sites.

Inclusion and exclusion criteria
--------------------------------

In order to be included, patients hospitalized between January 1, 2011, and December 31, 2012, had to have suspected or culture-proven IFI due to *Candida* or *Aspergillus*, must have received definitive antifungal drug therapy, and must have met at least one of the following additional criteria: surgical and/or medical patients at risk for IFI in the intensive care unit (ICU; stay must be ≥3 days in duration), patients with cancer and/or bone marrow transplant or stem cell transplant, patients who had undergone a solid organ transplant, and immunocompromised patients, including (but not limited to) those positive for HIV, diabetic patients, or those taking corticosteroids. These criteria aimed to include both patients with more typically observed and identified IFI risk factors (cancer, bone marrow/stem cell transplant, solid organ transplant) and patients meeting a broader definition for IFI risk, including those with an ICU admission ≥3 days.

Patient characteristics, treatment patterns, and outcomes
---------------------------------------------------------

Basic patient demographics were collected from the medical charts, including age, sex, weight, comorbid conditions, history of chemotherapy, and prior use of corticosteroids. Microbiologic identification, site of IFI confirmatory culture, and antifungal sensitivities were collected as reported by the abstracting physician. Antifungal therapy treatment patterns were collected in detail to include drug, dose, route, timing (days to start antifungal treatment), and changes in therapy.

Data collection for patterns of health care resource use included the following: pathological tests, microbiological/virological tests, laboratory tests, radiological/imaging tests, procedures such as days of mechanical ventilation and dialysis/renal replacement therapy, and length of hospital stay, overall and by location (emergency department, ICU, regular ward, intermediate care/high dependency unit).

Clinical outcomes collected included overall in-hospital mortality (IFI related and non-IFI related), relapse and/or rehospitalization for IFI or rehospitalization for any reason within 30 days post discharge, and clinical response of IFI cases at the time of discharge (clinical cure, improvement, failure, indeterminate).

Statistical analysis
--------------------

Binary and categorical end points were summarized in terms of percentages in each category, and continuous variables were presented using number of observations (when less than the entire sample), arithmetic mean, and standard deviation. As a descriptive study for each country, no *P*-values are provided for between-country or between-site comparisons.

Results
=======

Patient-level demographic and clinical characteristics
------------------------------------------------------

Detailed medical chart data were collected for 102 patients across the five study sites, 51 from Saudi Arabia and 51 from Lebanon. The majority of the patients were indicated by the study investigator to be immunocompromised (81%; [Table 1](#t1-idr-10-035){ref-type="table"}). Other common reasons for inclusion were ICU admission ≥3 days (51%) and cancer and/or bone marrow transplant or stem cell transplant (45%). Only two patients (2%) were solid organ transplant recipients.

Almost all patients (92%) had at least one comorbidity ([Table 1](#t1-idr-10-035){ref-type="table"}). The mean number of comorbid conditions per patient was 2.4, with the most common conditions being diabetes, coronary artery disease, and leukemia. A small proportion of patients were receiving antifungals (10%) or corticosteroids (20%) prior to admission, and 26% of patients had received chemotherapy within the 90 days prior to admission.

Of the 102 IFI patients, 100 (98%) had culture results available, and of these, 78 (78%) had at least one positive culture. Patients most frequently had positive cultures collected from blood (44%), pulmonary sites (33%), and urine (28%). [Figure 1](#f1-idr-10-035){ref-type="fig"} shows the microbiologic profile of available *Candida* and *Aspergillus* cultures. For *Candida* infections (n=70 cultures), 56% were *C. albicans*, 20% were *Candida tropicalis*, 14% were *Candida glabrata*, and 13% were another type of *Candida*. For *Aspergillus* cultures (n=10), 60% were *Aspergillus fumigatus*, 10% were *Aspergillus niger*, 10% were *Aspergillus flavus*, and 20% were unknown. Two patients (2%) had positive cultures for both *Candida* and *Aspergillus. Aspergillus* galactomannan antigen testing was performed in 11% of patients.

Antifungal treatment patterns
-----------------------------

[Table 2](#t2-idr-10-035){ref-type="table"} shows the susceptibility profile as reported by the abstracting physician for the 29 *Candida* specimens tested for antifungal susceptibility. All susceptibility results were reported in patients from Saudi Arabia; no testing was performed in Lebanon or in *Aspergillus* isolates from either country. Only 62% and 35% of specimens were sensitive to fluconazole and itraconazole, respectively. While some specimens were sensitive to flucytosine and itraconazole ([Table 2](#t2-idr-10-035){ref-type="table"}), these agents ultimately were not prescribed to any of the patients included in this study.

The median time from admission to diagnosis was 6 days (range 0 to 92 days), and active therapy was initiated at a median of 1 day thereafter (range 0 to 93 days post admission). Among the 62 patients who had both a culture collected and active therapy initiated, a median of 2.5 days (range −3 to 80 days) passed between these events.

Overall, 78 patients (76%) received at least one antifungal considered to be active against the infecting fungal species. The 102 IFI patients were prescribed a total of 111 first-line drugs, with nearly two-thirds including fluconazole ([Figure 2](#f2-idr-10-035){ref-type="fig"}). Forty-two patients (41%) required a total of 43 second-line drugs, with 26% of patients discontinuing the first-line regimen due to lack of response. The most commonly selected second-line antifungals were voriconazole (35%) and caspofungin (30%). Eleven patients (11%) required a total of 13 third-line drugs, with the most common being amphotericin B (36%).

Health care resource utilization
--------------------------------

[Table 3](#t3-idr-10-035){ref-type="table"} highlights key health care resource utilization across both countries. Patients with IFI stayed in the hospital for a mean of 32 days and spent the majority of that time in general wards (19 days across all patients), while 55% of patients required admission to an ICU. Thirty-eight patients with IFI (37%) required mechanical ventilation, with a mean duration of 13.7 days per patient. In addition, eleven patients (11%) required hemodialysis for a mean of 14.6 days.

Clinical outcomes
-----------------

[Table 4](#t4-idr-10-035){ref-type="table"} shows the clinical outcomes with 42% of patients dying in the hospital; however, the cause of death included IFI in only 33%. Few patients relapsed or were rehospitalized for IFI (2% for both).

Discussion
==========

This is the first real-world observational study of IFI in the Middle East that comprehensively assessed the mortality, treatment patterns, and resource use burden. Our results indicate that IFI represents a substantial burden to hospitals in the Middle East, with significant unmet needs, including delays in time to active therapy initiation, low utilization of rapid diagnostic tests, and suboptimal antifungal treatment, all of which may have impacted the high mortality rates and extended length of hospital stay seen in this population.

In patients with IFI, difficulty in recognizing the infection as fungal may lead to delays in initiation of antifungal therapy. In this study, the median time from admission to diagnosis was 6 days, and antifungal therapy was delayed by an additional day. Previous studies have shown a clear relationship between time to initiation of antifungal therapy and in-hospital mortality, with delays as short as 12 hours associated with increased risk of mortality.[@b3-idr-10-035] Despite the long delays to antifungal therapy in this study, in-hospital mortality was similar to that seen in previous studies.[@b3-idr-10-035]--[@b6-idr-10-035]

Over two-thirds of patients with IFI received fluconazole as part of their first-line antifungal regimen, which is likely due to its historical position as a first-line antifungal in clinical practice guidelines and low cost. However, antifungal susceptibility testing revealed that only 62% of the tested *Candida* isolates were sensitive to fluconazole and 42% of patients were switched to a second antifungal regimen. The use of initial antifungal regimens that are not active against the infecting organism can lead to further delays in the initiation of appropriate antifungal therapy, which could further worsen clinical outcomes. Recent guidelines in the Middle East recommend the echinocandins as the first-line agents for *Candida*, given emerging resistance to fluconazole.[@b2-idr-10-035]

IFIs have a significant impact on the morbidity and mortality of immunocompromised patients and are also known to affect nontypical hosts such as patients with medical comorbidities and those in the ICU.[@b7-idr-10-035],[@b8-idr-10-035] A combination of typical (cancer, bone marrow/stem cell transplant, solid organ transplant) and nontypical (ICU admission ≥3 days) risk factors were used in the selection of patients for this study; however, less than half of the study patients had at least one typical risk factor. The findings in this study highlight the trends in other regions that nontypical hosts with comorbidities such as cardiovascular, pulmonary, and renal diseases represent key patient populations at risk for developing IFI.[@b8-idr-10-035],[@b9-idr-10-035] Earlier consideration for the potential of IFI in medically comorbid patients may reduce the time to antifungal treatment and improve outcomes.

The economics of IFI are driven by the length of hospitalization including ICU, general ward stay and the total length of stay. Antifungal treatment and cost are dependent on the antifungal chosen, weight of the patient for weight-based therapies, and duration of therapy. In this study, by simply documenting the current resource use burden for hospitals managing IFI patients and the suboptimal application of rapid diagnostic testing and antifungal treatment (despite current guidelines in the Middle East for IFI), the hope is that improvements in care may be achieved.[@b1-idr-10-035],[@b2-idr-10-035] The costs attributable to resource utilization, such as hospitalization, would be expected to vary across countries due to differences in practices and health care systems.

This study has a number of potential limitations associated with retrospective research, including representativeness beyond the countries involved in data collection and selection bias. We were unable to attribute health care resource utilization that occurred specifically due to IFI versus for underlying conditions within the patient; as such, resource utilization represents an all-cause, not disease-specific, utilization among IFI patients. Nevertheless, this study represents the first comprehensive attempt to benchmark the real-world clinical and economic burden of IFI in countries within the Middle East. Research in other countries would be needed to confirm the findings reported here.

Conclusion
==========

This real-world observational study demonstrates that many patients from the sites in Lebanon and Saudi Arabia who developed IFI included hosts with a variety of comorbidities that may put them at risk for fungal infections. Clinical and economic outcomes in this population demonstrate significant burden with high mortality risk and long hospitalizations and suboptimal use of antifungal agents. The results of this study may encourage use of clinical guidelines to treat IFI in the Middle East.
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![Microbiologic profile of invasive fungal infections.\
**Notes:** (**A**) *Candida* (n=70 cultures). n=2 patients cultured both *Candida albicans* and *Candida glabrata*. Other *Candida* included *C. parapsilosis* (n=3), *C. famata* (n=2), *C. krusei* (n=1), *C. lusitaniae* (n=1), *C. rugosa* (n=1), and non-albicans (otherwise unspecified, n=1). (**B**) *Aspergillus* (n=10 cultures).\
**Abbreviations:** *C. albicans, Candida albicans; C. glabrata, Candida glabrata; C. parapsilosis, Candida parapsilosis; C. famata, Candida famata; C. krusei, Candida krusei; C. lusitaniae, Candida lusitaniae; C. rugosa, Candida rugosa; C. tropicalis, Candida tropicalis; A. fumigatus, Aspergillus fumigatus; A. niger, Aspergillus niger; A. flavus, Aspergillus flavus*.](idr-10-035Fig1){#f1-idr-10-035}

![Medications utilized for invasive fungal infection treatment.](idr-10-035Fig2){#f2-idr-10-035}

###### 

Patient profile -- IFI

  -----------------------------------------------------------------------------------------------------------------------------------------------
                                                                                                          Overall\    Saudi Arabia\   Lebanon\
                                                                                                          (N=102)     (n=51)          (n=51)
  ------------------------------------------------------------------------------------------------------- ----------- --------------- -----------
  Male, %                                                                                                 55          55              55

  Age at hospital admission, mean ± SD                                                                    55.2±25.1   56.8±25.5       53.6±25.0

  Any comorbidities, %                                                                                    92          92              92

   Number of reported comorbidities, mean ± SD                                                            2.4±1.7     2.4±1.7         2.4±1.7

   Diabetes, %                                                                                            41          55              27

   Coronary artery disease, %                                                                             24          12              35

   Leukemia, %                                                                                            19          10              27

   Moderate-to-severe renal disease, %                                                                    16          14              18

   Congestive heart failure, %                                                                            15          16              14

   Chronic pulmonary disease, %                                                                           15          12              18

   Cerebrovascular disease, %                                                                             14          20              8

   Hypertension, %                                                                                        9           14              4

  Criteria met to be included in study, %                                                                                             

   Surgical and/or medical patient at risk for IFI in the ICU[a](#tfn1-idr-10-035){ref-type="table-fn"}   51          47              55

   Has/had cancer and/or is a bone marrow or stem cell transplant patient                                 45          31              59

   Had undergone a solid organ transplant                                                                 2           2               2

   Immunocompromised                                                                                      81          76              86

  Drug use prior to admission                                                                                                         

   Antifungals prior to admission, %                                                                      10          0               20

   Corticosteroids prior to admission, %                                                                  20          6               33

   Chemotherapy within 90 days prior to admission, %                                                      26          6               47

  Days from hospital admission to diagnosis, %                                                                                        

   Within 2 days of admission                                                                             34          53              16

   After 2 days of admission                                                                              66          47              84

  ANC                                                                                                                                 

   Patients with valid information, n                                                                     27          3               24

   Neutropenic (ANC \<500 cells/μL), %                                                                    11          0               13
  -----------------------------------------------------------------------------------------------------------------------------------------------

**Note:**

ICU stay must be at least 72 hours in duration.

**Abbreviations:** IFI, invasive fungal infection; ICU, intensive care unit; ANC, absolute neutrophil count.

###### 

Invasive fungal infection susceptibility profile[a](#tfn3-idr-10-035){ref-type="table-fn"}

  Antifungal       N tested   \% sensitive
  ---------------- ---------- --------------
  Caspofungin      8          100
  Amphotericin B   28         96
  Voriconazole     19         79
  Flucytosine      21         71
  Fluconazole      29         62
  Itraconazole     17         35

**Notes:**

Susceptibility as reported by the abstracting physician. No specific minimum inhibitory concentration-fold parameters were provided to abstracting physicians; this was based on their clinical judgment.

###### 

IFI health care resource utilization

  ------------------------------------------------------------------------------------------------------------
                                                                     Total\       Saudi Arabia\   Lebanon\
                                                                     (N=102)      (n=51)          (n=51)
  ------------------------------------------------------------------ ------------ --------------- ------------
  Total LOS (days), mean ± SD                                        32.4±28.6    39.0±35.9       25.9±16.7

  ER, n (%)                                                          7 (6.9%)     7 (13.7%)       0 (0.0%)

   Days spent in ER, mean ± SD                                       3.3±0.5      3.3±0.5         --

  General ward, n (%)                                                66 (64.7%)   44 (86.3%)      22 (43.1%)

   Days spent in general ward, mean ± SD                             29.4±32.4    32.0±36.5       24.2±22.1

  HDU/Intermediate, n (%)                                            25 (24.5%)   0 (0%)          25 (49%)

   Days spent in HDU/intermediate, mean ± SD                         15.3±10.1    --              15.3±10.1

  ICU, n (%)                                                         56 (54.9%)   27 (52.9%)      29 (56.9%)

   Days spent in ICU, mean ± SD                                      17.2±14.1    20.6±15.7       14.1±11.8

  Mechanical ventilation, n (%)                                      38 (37.3%)   13 (25.5%)      25 (49.0%)

   Days spent with mechanical ventilation, mean ± SD                 13.7±13.2    15.3±12.2       12.8±13.8

  Dialysis, n (%)                                                    11 (10.8%)   7 (13.7%)       4 (7.8%)

   Days spent at the dialysis unit, mean ± SD                        14.6±14.2    18.0±16.7       8.8±6.6

  Proportion with tests/procedures supporting IFI diagnosis, n (%)                                

   Chest radiograph                                                  86 (84.3%)   38 (74.5%)      48 (94.1%)

   Bronchoalveolar lavage-PCR                                        12 (11.8%)   3 (5.9%)        9 (17.6%)

   Galactomannan antigen                                             11 (10.8%)   2 (3.9%)        9 (17.6%)
  ------------------------------------------------------------------------------------------------------------

**Abbreviations:** IFI, invasive fungal infection; LOS, length of stay; ER, emergency room; HDU, high dependency unit; ICU, intensive care unit; PCR, polymerase chain reaction; --, data not available.

###### 

IFI mortality and 30-day relapse/rehospitalization

  -----------------------------------------------------------------------------------------------------------------
  Outcome                                                                     Overall\   Saudi Arabia\   Lebanon\
                                                                              (N=102)    (n=51)          (n=51)
  --------------------------------------------------------------------------- ---------- --------------- ----------
  In-hospital mortality, %                                                    42         35              49

  Cause of death[a](#tfn5-idr-10-035){ref-type="table-fn"}                                               

   Underlying disease-related complication, %                                 72         94              56

   IFI related, %                                                             33         6               52

   Other, %                                                                   7          11              4

  Outcomes 30 days post discharge[b](#tfn6-idr-10-035){ref-type="table-fn"}                              

   Relapse of IFI, %                                                          2          3               0

   Rehospitalization for IFI, %                                               2          3               0

   Rehospitalization, any reason, %                                           14         9               19
  -----------------------------------------------------------------------------------------------------------------

**Notes:**

Multiple causes of death could be listed.

Only measured in patients discharged alive (n=59 overall, 33 from Saudi Arabia and 26 from Lebanon).

**Abbreviation:** IFI, invasive fungal infection.
